Preparation of risperidone
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsBarnaba Krochmal, Dov Diller, Ben-Zion Dolitzky, Judith Aronhime
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the novel forms of risperidone, designated Form A, Form B and Form E. Methods for their preparation are also disclosed. The present invention also relates to processes for making risperidone. Pharmaceutical compositions containing the new forms of risperidone and methods of using them are also disclosed.
Claims22
A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.7±0.2 degrees two-theta.
A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by a x-ray powder diffraction pattern substantially as depicted in FIG. 2.
A solid or solid-containing pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carriers and pharmaceutical acceptable excipients, wherein the active ingredient consists essentially of a crystalline form of risperidone characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.7±0.2 degrees two-theta.
A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.3±0.2 degrees two-theta.
A solid or solid-containing pharmaceutical formulation comprising a crystalline form of risperidone with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable excipient, wherein the crystalline form of risperidone is characterized by a x-ray powder diffraction pattern sub stantially as depicted in FIG. 1.
A solid or solid-containing pharmaceutical dosage formulation comprising an active ingredient and at least one component selected from the group consisting of pharmaceutical acceptable carriers and pharmaceutical acceptable excipients, wherein the active ingredient consists essentially of a crystalline form of risperidone characterized by x-ray powder diffraction peaks at 14.0±0.2 and 21.3±0.2 degrees two-theta.
Dependencies are inferred from the claim text.